Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has announced the granting of inducement awards to five new employees. The awards, approved by the Compensation Committee on April 1, 2025, consist of non-statutory stock options to purchase a total of 228,000 shares of common stock under the company's 2024 Inducement Plan.

The stock options have an exercise price of $6.26 per share, matching Immunome's closing price on April 1, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $6.26 per share, the Company’s closing sales price on April 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant.

About Immunome

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC which is currently in a Phase 1 trial, and IM-3050, a FAP-targeted radioligand, which is the subject of a recently submitted IND. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403273378/en/

Investor Contact

Max Rosett

Chief Financial Officer

investors@immunome.com

Source: Immunome, Inc.

FAQ

How many shares are included in Immunome's (IMNM) April 2025 inducement stock options grant?

Immunome granted stock options to purchase 228,000 shares of common stock.

What is the exercise price for Immunome's (IMNM) April 2025 inducement stock options?

The exercise price is $6.26 per share, equal to Immunome's closing price on April 1, 2025.

What is the vesting schedule for Immunome's (IMNM) April 2025 inducement grants?

The options vest over 4 years - 25% after one year and the remainder monthly over 36 months.

How many employees received Immunome's (IMNM) April 2025 inducement grants?

Five new employees received the inducement grants.